432 related articles for article (PubMed ID: 33427102)
1. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
[TBL] [Abstract][Full Text] [Related]
2. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
3. An
Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
5. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.
Jaiswal G; Yaduvanshi S; Kumar V
J Biomol Struct Dyn; 2022 Sep; 40(14):6671-6681. PubMed ID: 33645443
[TBL] [Abstract][Full Text] [Related]
6. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
Pourmand S; Zareei S; Shahlaei M; Moradi S
Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
Othman H; Bouslama Z; Brandenburg JT; da Rocha J; Hamdi Y; Ghedira K; Srairi-Abid N; Hazelhurst S
Biochem Biophys Res Commun; 2020 Jun; 527(3):702-708. PubMed ID: 32410735
[TBL] [Abstract][Full Text] [Related]
10. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
11. Computational exploration of natural peptides targeting ACE2.
He M; Wang Y; Huang S; Zhao N; Cheng M; Zhang X
J Biomol Struct Dyn; 2022 Oct; 40(17):8018-8029. PubMed ID: 33826484
[TBL] [Abstract][Full Text] [Related]
12. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
Dehury B; Raina V; Misra N; Suar M
J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
[TBL] [Abstract][Full Text] [Related]
13. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
14. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.
Miroshnychenko KV; Shestopalova AV
J Biomol Struct Dyn; 2022; 40(19):8672-8686. PubMed ID: 33896392
[TBL] [Abstract][Full Text] [Related]
15. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
[TBL] [Abstract][Full Text] [Related]
16. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
[TBL] [Abstract][Full Text] [Related]
17. Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein.
Sarto C; Florez-Rueda S; Arrar M; Hackenberger CPR; Lauster D; Di Lella S
Biol Chem; 2022 Apr; 403(5-6):615-624. PubMed ID: 35357791
[TBL] [Abstract][Full Text] [Related]
18. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
19. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
Lata S; Akif M
J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
[TBL] [Abstract][Full Text] [Related]
20. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
